The striking gains in functional capacity and quality of life conferred by baroreflex activation therapy in patients with heart failure, as shown in the pivotal phase 3 clinical trial for this novel ...

SAN DIEGO, CA — In a small trial of patients with heart failure and reduced ejection fraction (HF-REF), those who were implanted with the Barostim neo (CVRx) device, which stimulates baroreceptors in ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In certain patients with HF with reduced ejection fraction, baroreflex activation therapy was ...

SAN FRANCISCO, CA—In patients with heart failure with reduced ejection fraction (HFrEF) who are not candidates for cardiac resynchronization therapy, baroreflex activation therapy (BAT) provides at ...

TUCSON, Ariz. (KVOA) - Carondelet St. Mary's Hospital has successfully completed its first implantation of the Barostim™ Baroreflex Activation Therapy device, marking a significant advancement in the ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The heart of a 67-year-old patient is working more efficiently these days thanks to the cardiac team at Cooper University Health Care and a “cutting-edge treatment option.” On March 29, the ...

ALBANY — Doctors at Albany Medial Center have successfully implanted a groundbreaking, recently FDA-approved heart failure device designed to treat patients who haven't had success with other ...

MINNEAPOLIS, Aug. 16, 2019 /PRNewswire/ -- CVRx, Inc., a private medical device company, announced today that it has received Premarket Approval (PMA) from the United States Food and Drug ...